Contraception
Volume 81, Issue 1 , Pages 49-56 , January 2010

Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits

Received 5 November 2008 ,Revised 19 May 2009 ,Accepted 11 June 2009.

References 

  1. Society of Consumer Goods Research (Gesellschaft für Konsumgüterforschung). Survey on prevalence of depressive mood and other psychical disorders in German women. Dec 2005–Jan 2006. unpublished.
  2. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception. 2005;71:1–7
  3. Bock K, Heskamp ML, Schramm G. Influence of chlormadinone acetate on dysmenorrhea and other cycle-related complaints (original in German language). Gyne. 2008;8:219–225
  4. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Clin Drug Invest. 2002;22:221–231
  5. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara®: efficacy, tolerability and anti-androgenic properties. Contraception. 2003;67:305–312
  6. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007;76:84–90
  7. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara®. Contraception. 1998;57:103–109
  8. Worret I, Arp W, Zahradnik HP, Andreas JE, Binder N. Acne resolution rates: results of a single-blind, randomised, controlled, parallel phase III trial with EE/CMA (Belara®) and EE/LNG (Microgynon®). Dermatology. 2001;203:38–44
  9. Huber JC, Heskamp MLS, Schramm GAK. Effect of an oral contraceptive with chlormadinone acetate on depressive mood. Analysis of data from four observational studies. Clin Drug Invest. 2008;28:783–791
  10. American College of Obstetricians and Gynecologists (ACOG) . Premenstrual syndrome. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2000;[Apr. 9 (ACOG practice bulletin; no. 15) (reaffirmed 2005)]
  11. Connolly M. Premenstrual syndrome: an update on definitions, diagnosis and management. Adv Psychiatr Treat. 2001;7:469–477
  12. Merki-Feld GS. Cardiovascular risks associated with low-dose combined oral contraceptives. Ther Umsch. 2001;58:564–569
  13. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–421
  14. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501
  15. Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Rev. 1999;29:196–217
  16. Zinder O, Dar DE. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol Scand. 1999;167:181–188
  17. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61:676–697

PII: S0010-7824(09)00311-4

doi: 10.1016/j.contraception.2009.06.011

Contraception
Volume 81, Issue 1 , Pages 49-56 , January 2010

Article Tools

* Image Usage & Resolution